全文获取类型
收费全文 | 1253436篇 |
免费 | 96390篇 |
国内免费 | 1555篇 |
专业分类
耳鼻咽喉 | 16295篇 |
儿科学 | 40849篇 |
妇产科学 | 34940篇 |
基础医学 | 187741篇 |
口腔科学 | 34696篇 |
临床医学 | 117029篇 |
内科学 | 245079篇 |
皮肤病学 | 27257篇 |
神经病学 | 101026篇 |
特种医学 | 46715篇 |
外国民族医学 | 265篇 |
外科学 | 177931篇 |
综合类 | 25696篇 |
现状与发展 | 3篇 |
一般理论 | 568篇 |
预防医学 | 103760篇 |
眼科学 | 27974篇 |
药学 | 92219篇 |
6篇 | |
中国医学 | 1951篇 |
肿瘤学 | 69381篇 |
出版年
2018年 | 13529篇 |
2017年 | 10390篇 |
2016年 | 11321篇 |
2015年 | 13079篇 |
2014年 | 18001篇 |
2013年 | 27478篇 |
2012年 | 37576篇 |
2011年 | 39969篇 |
2010年 | 23054篇 |
2009年 | 22256篇 |
2008年 | 37752篇 |
2007年 | 40383篇 |
2006年 | 39963篇 |
2005年 | 39098篇 |
2004年 | 37543篇 |
2003年 | 35841篇 |
2002年 | 34763篇 |
2001年 | 55891篇 |
2000年 | 56865篇 |
1999年 | 47723篇 |
1998年 | 12442篇 |
1997年 | 11302篇 |
1996年 | 11705篇 |
1995年 | 11812篇 |
1994年 | 11023篇 |
1993年 | 10313篇 |
1992年 | 38126篇 |
1991年 | 37656篇 |
1990年 | 36419篇 |
1989年 | 35240篇 |
1988年 | 32649篇 |
1987年 | 32005篇 |
1986年 | 30496篇 |
1985年 | 28761篇 |
1984年 | 21901篇 |
1983年 | 19127篇 |
1982年 | 11302篇 |
1981年 | 10255篇 |
1979年 | 20878篇 |
1978年 | 15355篇 |
1977年 | 12719篇 |
1976年 | 11780篇 |
1975年 | 12772篇 |
1974年 | 15550篇 |
1973年 | 15323篇 |
1972年 | 14497篇 |
1971年 | 13539篇 |
1970年 | 12758篇 |
1969年 | 12048篇 |
1968年 | 11214篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
991.
Elderly patients' and nurses' assessment of traditional bed bath compared to prepacked single units – randomised controlled trial 下载免费PDF全文
992.
Lori F. Maxfield Peter Abbink Kathryn E. Stephenson Erica N. Borducchi David Ng'ang'a Marinela M. Kirilova Noelix Paulino Michael Boyd Paul Shabram Qian Ruan Mayank Patel Dan H. Barouch 《Clinical and Vaccine Immunology : CVI》2015,22(11):1166-1175
Replication-competent adenovirus (rcAd)-based vaccine vectors may theoretically provide immunological advantages over replication-incompetent Ad vectors, but they also raise additional potential clinical and regulatory issues. We produced replication-competent Ad serotype 26 (rcAd26) vectors by adding the E1 region back into a replication-incompetent Ad26 vector backbone with the E3 or E3/E4 regions deleted. We assessed the effect of vectorization on the replicative capacity of the rcAd26 vaccines. Attenuation occurred in a stepwise fashion, with E3 deletion, E4 deletion, and human immunodeficiency virus type 1 (HIV-1) envelope (Env) gene insertion all contributing to reduced replicative capacity compared to that with the wild-type Ad26 vector. The rcAd26 vector with E3 and E4 deleted and containing the Env transgene exhibited 2.7- to 4.4-log-lower replicative capacity than that of the wild-type Ad26 in vitro. This rcAd26 vector is currently being evaluated in a phase 1 clinical trial. Attenuation as a result of vectorization and transgene insertion has implications for the clinical development of replication-competent vaccine vectors. 相似文献
993.
994.
995.
996.
Frank Wegmann Amin E. Moghaddam Torben Schiffner Kate H. Gartlan Timothy J. Powell Rebecca A. Russell Matthijs Baart Emily W. Carrow Quentin J. Sattentau 《Clinical and Vaccine Immunology : CVI》2015,22(9):1004-1012
The continued discovery and development of adjuvants for vaccine formulation are important to safely increase potency and/or reduce the antigen doses of existing vaccines and tailor the adaptive immune response to newly developed vaccines. Adjuplex is a novel adjuvant platform based on a purified lecithin and carbomer homopolymer. Here, we analyzed the adjuvant activity of Adjuplex in mice for the soluble hemagglutinin (HA) glycoprotein of influenza A virus. The titration of Adjuplex revealed an optimal dose of 1% for immunogenicity, eliciting high titers of HA-specific IgG but inducing no significant weight loss. At this dose, Adjuplex completely protected mice from an otherwise lethal influenza virus challenge and was at least as effective as the adjuvants monophosphoryl lipid A (MPL) and alum in preventing disease. Adjuplex elicited balanced Th1-/Th2-type immune responses with accompanying cytokines and triggered antigen-specific CD8+ T-cell proliferation. The use of the peritoneal inflammation model revealed that Adjuplex recruited dendritic cells (DCs), monocytes, and neutrophils in the context of innate cytokine and chemokine secretion. Adjuplex neither triggered classical maturation of DCs nor activated a pathogen recognition receptor (PRR)-expressing NF-κB reporter cell line, suggesting a mechanism of action different from that reported for classical pathogen-associated molecular pattern (PAMP)-activated innate immunity. Taken together, these data reveal Adjuplex to be a potent and well-tolerated adjuvant with application for subunit vaccines. 相似文献
997.
Myrna M. Miller Kristine E. Bennett Barbara S. Drolet Robbin Lindsay James O. Mecham Will K. Reeves Hana M. Weingartl William C. Wilson 《Clinical and Vaccine Immunology : CVI》2015,22(8):930-937
Rift Valley fever virus (RVFV) causes serious disease in ruminants and humans in Africa. In North America, there are susceptible ruminant hosts and competent mosquito vectors, yet there are no fully licensed animal vaccines for this arthropod-borne virus, should it be introduced. Studies in sheep and cattle have found the attenuated strain of RVFV, MP-12, to be both safe and efficacious based on early testing, and a 2-year conditional license for use in U.S. livestock has been issued. The purpose of this study was to further determine the vaccine''s potential to infect mosquitoes, the duration of humoral immunity to 24 months postvaccination, and the ability to prevent disease and viremia from a virulent challenge. Vaccination experiments conducted in sheep found no evidence of a potential for vector transmission to 4 North American mosquito species. Neutralizing antibodies were elicited, with titers of >1:40 still present at 24 months postvaccination. Vaccinates were protected from clinical signs and detectable viremia after challenge with virulent virus, while control sheep had fever and high-titered viremia extending for 5 days. Antibodies to three viral proteins (nucleocapsid N, the N-terminal half of glycoprotein GN, and the nonstructural protein from the short segment NSs) were also detected to 24 months using competitive enzyme-linked immunosorbent assays. This study demonstrates that the MP-12 vaccine given as a single dose in sheep generates protective immunity to a virulent challenge with antibody duration of at least 2 years, with no evidence of a risk for vector transmission. 相似文献
998.
999.
1000.